

Gentherm Inc.

2017 Fourth Quarter and Full Year Results February 20, 2018



Forward-Looking Statement

Except for historical information contained herein, statements in this presentation are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this presentation are made as of the date hereof or as of the date specified and are based on management's current expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause the Company's actual performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that new products may not be feasible, sales may not increase, additional financing requirements may not be available, new competitors may arise or customers may develop their own products to replace the Company's products, currency exchange rates may change unfavorably, pricing pressures from customers may increase, the Company's workforce and operations could be disrupted by civil or political unrest in the countries in which the Company operates, free trade agreements may be altered in a manner adverse to the Company, medical device regulations could change in an unfavorable manner, oil and gas prices could fluctuate causing adverse consequences, and other adverse conditions in the industries in which the Company operates may negatively affect its results. The business outlook discussed in this presentation does not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof. The foregoing risks should be read in conjunction with the Company's annual report on Form 10-K for the year ended December 31, 2016 and subsequent reports filed with the Securities and Exchange Commission. Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Use of Non-GAAP Financial Measures

In evaluating its business, Gentherm Incorporated considers and uses Adjusted EBITDA as a supplemental measure of its operating performance. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, transaction expenses, debt retirement expenses, unrealized currency gain or loss and unrealized revaluation of derivatives. Management believes that Adjusted EBITDA is a meaningful measure of liquidity and the Company's ability to service debt because it provides a measure of cash available for such purposes. Management provides an Adjusted EBITDA measure so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis.

The term Adjusted EBITDA is not defined under GAAP, and is not a measure of operating income, operating performance or liquidity presented in accordance with GAAP. Adjusted EBITDA has limitations as an analytical tool, and when assessing the Company's operating performance, investors should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with GAAP. Gentherm compensates for these limitations by relying primarily on its GAAP results and using Adjusted EBITDA only supplementally.

Revenue and adjusted EBITDA

	Three Months Ended December 31,			Year Ended December 31,			
(In Thousands)	2017		2016		2017		2016
Product Revenues\$	257,185	\$	236,541	\$	985,683	\$	917,600
Net Income	(5,242)		20,036		35,227		76,598
Adjusted EBITDA, less CEO Transition							
Expense (1)(2)	38,982		37,075		148,126		146,051

- Full year revenue growth: 7.4% thereof 4.6% organic
- Fourth quarter revenue growth: 8.7% thereof 4.1% organic

⁽¹⁾ Does not include \$3.8M and \$6.7M of Transition Expenses during the three month period ended December 31, 2017 and the year ended 2017, respectively.

⁽²⁾ Adjusted EDITDA is a non-GAAP measure, see slide 9.

Automotive

2017 Highlights

- Launched systems on 141 vehicle nameplates with 22 OEMs
- Launched record number 28 steering wheel heater solutions
- Launched first thermoelectric Battery Thermal Management with German OEM and NA OEM
- Honda NA and Bosch Global Supplier of the Year Awards
- Acquisition of Etratech



































Automotive

2017 AWARDS

- Over \$1.2B in new awards across 21 customers
- Several high-volume CCS[™] platform awards
 - GM Trucks
- Hyundai Santa Fe
- Ford F-Series
- Acura MDX
- Ram Truck
- And more
- Expansion of Japanese OEM business with Subaru & Mazda
- Won first CCS content with a major luxury brand-Mercedes
- First major Chinese OEM awards of CCS and thermal convenience products Geely & Great Wall
- Won follow-on awards taking booked business to \$216M for BTM™

CSZ

2017 HIGHLIGHTS

- Thermal test chamber for a NASA space project
- Launched new FilteredFlo® Pediatric Underbody Blanket
- Successfully passed critical design review gate with US Airforce for non-invasive warming and cooling device
- Launched 100V Norm-O-Temp® providing a solution for the Japanese Normothermia market
- Awarded CSZ WarmAir® system with St. Joseph Heath Integrated Health Care System (17 hospital system)
- 3-year extension with our largest customer
- Completed direct sales force development





GPT

2017 HIGHLIGHTS

- Regulation drives methane reduction market ERA Grant
- Australian LNG market
- Expansion of offshore platform success to new areas





Adjusted Non-GAAP EPS

		nths Ended ember,	Year Ended December 31,		
	2017	2016	2017	2016	
Diluted EPS – As Reported	(0.14)	\$ 0.71	\$ 0.96	\$ 2.09	
Acquisition transaction expenses	0.02	_	0.02	0.02	
Non-cash purchase accounting impacts	0.09	0.08	0.30	0.42	
Unrealized currency loss (gain)	0.06	(0.17)	0.59	(0.17)	
CEO transition expenses	0.10	_	0.18	_	
Management reorganization	_	0.05	_	0.05	
Tax effect of above	(0.07)	0.01	(0.29)	(0.10)	
US Tax Reform	0.55	_	0.55	_	
North American reorganization withholding tax				0.28	
Diluted EPS – As Adjusted	0.61	\$ 0.68	\$ 2.31	\$ 2.59	

Reconciliation of Adjusted EBITDA

	Three Months Ended December 31,			Year Ended December 31,		
(In Thousands)	2017		2016	2017	2016	
Net Income (loss)	\$ (5,242)) \$	26,036	\$ 35,227	\$ 76,598	
Add Back:						
Income tax expense	23,79	5	6,319	34,028	33,965	
Interest expense	1,252	2	970	4,885	3,257	
Depreciation and amortization	12,238	3	9,993	44,685	37,592	
Adjustments:						
Acquisition transaction expense	789	9	50	789	743	
Unrealized currency loss (gain)	2,393	3	(6,293)	21,818	(6,104)	
Adjusted EBITDA	\$ 35,225	5 \$	37,075	\$ 141,432	\$ 146,051	
CEO transition expenses	3,757	7		6,694		
Adjusted EBITDA less CEO transition expenses	\$ 38,982	2 \$	37,075	\$ 148,126	\$ 146,051	

Selected Balance Sheet Data

(In Thousands)	December 31, 2017	September 30, 2017
Cash and Cash Equivalents	\$ 103,172	\$ 147,626
Total Assets	883,405	862,588
Working Capital (less cash)	186,582	184,911
Debt	144,669	145,891
Current	3,460	3,445
Non-Current	141,209	142,446
Revolving LOC Availability	220,697	203,780
Total Liquidity	323,869	351,406

2018 Guidance

- Revenue growth 8 10% (3 -5% organic)
- Gross margin 30 32%
- Adjusted EBITDA⁽¹⁾ approximately 15% of product revenue
- CAPEX approximately \$50M

⁽¹⁾ Due to the inherent difficulty of forecasting the timing and amount of certain items that would impact net income, such as foreign currency gains and losses, we are unable to reasonably estimate net income, the GAAP financial measure most directly comparable to Adjusted EBITDA. Accordingly, we are unable to provide a reconciliation of Adjusted EBITDA to net income with respect to the guidance provided.

